24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
LETROLIEVA 2.5MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | LETROLIEVA 2.5MG |
|---|---|
| Composition | Letrozole Tablets IP 2.5 mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Strip (10 x 10) |
| Country of Origin | India |
Letrozole Tablets IP 2.5 mg (Letrozole Tablets IP 2.5 mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
LETROLIEVA 2.5 MG (Letrozole Tablets IP 2.5 mg) is a prescription medicine used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It contains Letrozole 2.5 mg, a highly effective aromatase inhibitor that helps reduce estrogen levels in the body. Since certain breast cancers depend on estrogen for growth and survival, lowering estrogen levels can help slow or stop the growth of cancer cells.
Breast cancer is one of the most common cancers affecting women worldwide. In many cases, cancer cells possess hormone receptors that respond to estrogen. LETROLIEVA 2.5 MG works by blocking the aromatase enzyme, which is responsible for producing estrogen in postmenopausal women. By reducing estrogen production, the medicine helps prevent cancer cells from receiving the hormonal stimulation they need to grow.
Letrozole is widely used as part of modern hormone therapy and targeted breast cancer treatment programs. It may be prescribed after surgery, radiation therapy, chemotherapy, or as a long-term maintenance treatment to reduce the risk of cancer recurrence.
LETROLIEVA 2.5 MG is commonly prescribed for:
• Hormone Receptor-Positive Breast Cancer
• Early-Stage Breast Cancer
• Advanced Breast Cancer
• Metastatic Breast Cancer
• Adjuvant Hormonal Therapy
• Long-Term Breast Cancer Management
• Postmenopausal Breast Cancer Treatment
In addition to its role in oncology, Letrozole may sometimes be prescribed for fertility-related conditions under specialist supervision. However, its primary use remains breast cancer treatment and management.
Manufactured under stringent pharmaceutical quality standards, LETROLIEVA 2.5 MG is designed to provide consistent therapeutic performance and reliable treatment outcomes. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and hormone therapy.
Patients receiving Letrozole therapy may require regular medical monitoring, bone density assessments, cholesterol evaluations, and routine follow-up visits to ensure safe and effective treatment.
Due to its proven effectiveness in reducing breast cancer recurrence and supporting long-term disease control, LETROLIEVA 2.5 MG has become an essential medicine in modern breast cancer care.
LETROLIEVA 2.5 MG (Letrozole Tablets IP 2.5 mg) is primarily used for the treatment and management of hormone-sensitive breast cancer.
The medicine is widely used after surgery or other cancer treatments to reduce the risk of recurrence.
Doctors may prescribe Letrozole for advanced breast cancer to help slow disease progression.
LETROLIEVA may be used in patients whose cancer has spread to other parts of the body.
The medicine is specifically effective in cancers that depend on estrogen for growth.
Many patients receive Letrozole as part of long-term treatment plans to maintain disease control.
The medicine is commonly prescribed for postmenopausal women diagnosed with hormone-sensitive breast cancer.
Letrozole belongs to a class of medicines known as aromatase inhibitors.
LETROLIEVA works by:
• Blocking the aromatase enzyme
• Reducing estrogen production in the body
• Limiting hormonal stimulation of cancer cells
• Slowing tumor growth
• Helping prevent cancer recurrence
• Supporting long-term breast cancer management
This targeted hormonal mechanism helps control disease progression and improve treatment outcomes.
Like all prescription medicines, LETROLIEVA 2.5 MG may cause side effects in some patients. Side effects vary depending on individual health conditions and treatment duration.
Episodes of warmth, flushing, or sweating are frequently reported.
Pain, stiffness, or discomfort in joints may occur during treatment.
Patients may experience weakness, tiredness, or reduced energy levels.
Mild to moderate headaches may develop during therapy.
Some individuals may experience excessive sweating.
Bone discomfort or musculoskeletal pain may occur.
Mild nausea or digestive discomfort may develop.
Patients may occasionally experience dizziness or lightheadedness.
Some individuals may notice minor weight gain or weight fluctuations.
Seek immediate medical attention if you experience:
• Severe chest pain
• Signs of stroke
•Severe allergic reactions
• Persistent bone fractures
• Significant swelling
• Severe breathing difficulty
• Vision changes
• Unusual weakness
Patients should immediately consult their healthcare provider if serious symptoms occur.
The dosage of LETROLIEVA 2.5 MG (Letrozole Tablets IP 2.5 mg) should always be determined by a qualified healthcare professional.
Treatment requirements depend on the cancer stage and hormone receptor status.
Previous surgery, chemotherapy, radiation therapy, or hormone therapy may influence treatment planning.
Age, medical history, and overall health play a role in dosage recommendations.
Doctors may monitor treatment effectiveness and adjust therapy if necessary.
Bone density monitoring may be important during long-term treatment.
• Take the tablet exactly as prescribed.
• Swallow the tablet whole with water.
• Take the medicine at the same time every day.
• Continue treatment as directed by your doctor.
• Do not skip doses or stop treatment without medical advice.
• Attend all scheduled follow-up appointments.
Consistent use helps maximize treatment effectiveness.
Before starting treatment, patients should inform their doctor if they have:
• Osteoporosis or low bone density
• Liver disease
• High cholesterol
• Heart disease
• Previous hormone therapy complications
• Allergies to medications
Patients should also disclose all medicines, supplements, and herbal products they are taking to prevent possible drug interactions.
This medicine is generally intended for postmenopausal women. Pregnant or breastfeeding women should not use Letrozole unless specifically instructed by a healthcare professional.
• Store in a cool and dry place.
• Protect from direct sunlight and moisture.
• Keep out of reach of children.
• Store at recommended room temperature.
• Trusted Letrozole formulation
• Effective hormone therapy for breast cancer
• Supports long-term disease management
• Helps reduce breast cancer recurrence risk
• Manufactured under strict pharmaceutical quality standards
• Suitable for modern oncology treatment protocols
• Reliable option for postmenopausal breast cancer care
It is primarily used for the treatment and management of hormone receptor-positive breast cancer in postmenopausal women.
Letrozole is an aromatase inhibitor that reduces estrogen production and helps slow the growth of hormone-sensitive breast cancer cells.
No, it is a hormone therapy medicine that works differently from traditional chemotherapy.
Yes, it is commonly used after primary cancer treatment to reduce the risk of recurrence.
Yes, long-term use may reduce bone density, which is why regular monitoring is often recommended.
Yes, doctors may recommend bone density tests, cholesterol monitoring, and routine medical evaluations during treatment.
No, treatment should only be modified or discontinued under medical supervision.
Yes, this medicine should always be used under the guidance of qualified healthcare professionals experienced in oncology and hormone therapy.